Mitochondrial Myopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mitochondrial Myopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Mitochondria are known as “the powerhouse of the cell,” but when defects occur they give rise to mitochondrial diseases. Mitochondrial diseases affecting the muscles are known as mitochondrial myopathies. These can occur because of fetal gene mutations in the mitochondria, resulting in childhood myopathies. Symptoms include fatigue, muscle weakness, stunted growth, and exercise intolerance, as production of adenosine triphosphate (ATP), a cellular fuel, is reduced. This can lead to cardiac, respiratory, and neurological complications, among others. Diagnosis is done based on the history of familial hereditary diseases, followed by physical and laboratory examinations like muscle biopsy, imaging to eliminate other neurological and cardiac diseases, and metabolic complications. Management of this condition is mainly symptomatic and to prevent complications. Physical exercise is prescribed to improve muscle condition and dexterity, and nutrient supplements can play a role.
The Mitochondrial Myopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mitochondrial Myopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mitochondrial Myopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mitochondrial Myopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mitochondrial Myopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mitochondrial Myopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abliva ABBeiwe Inc
Entrada Therapeutics Inc
Ixchel Pharma LLC
Mitobridge Inc
OMEICOS Therapeutics GmbH
Precision Biosciences Inc
PTC Therapeutics Inc
Reneo Pharmaceuticals Inc
Stealth BioTherapeutics Inc.
Travere Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mitochondrial Myopathy reports